Imara Funding: How Much Did They Raise & Key Investors

How Much Did Imara Raise?
Funding & Key Investors

Imara, Inc. has solidified its position in the biotechnology sector, securing a total capital infusion of $94M. This trajectory of financial backing, highlighted by a recent strategic investment of $63M, underscores the market confidence in the company's specialized approach to treating hemoglobinopathies. By leveraging significant institutional support, Imara continues to advance its clinical pipeline, moving from early-stage research toward robust multi-national trials.

The company's growth narrative is defined by a disciplined progression of financing rounds, beginning with its Series A in 2016 and culminating in its Series B in 2019. This capital structure provides the necessary runway to transition from foundational development to complex, large-scale therapeutic validation.

What is Imara?

Imara

Manufacturing

Pharmaceuticals

Business Services

Imara is a clinical-stage biopharmaceutical firm focused on the development of novel therapeutics for patients suffering from sickle cell disease and other hemoglobinopathies. The company's primary asset, IMR-687, is a highly selective, potent small molecule inhibitor of PDE9. By targeting the underlying pathology of sickle cell disease—specifically by reducing red blood cell sickling and white blood cell adherence—Imara aims to mitigate the frequency of vaso-occlusive crises. Currently, the firm is navigating a multi-national Phase 2a study in adult patients, with strategic plans to expand clinical evaluation into pediatric populations and beta thalassemia cohorts.

How much funding has Imara raised?

Imara has raised a total of $94M across 2 funding rounds:

2016

Series A

$31M

2019

Series B

$63M

Series A (2016): $31M with participation from Bay City Capital, Alexandria Venture Investments., Lundbeckfond Ventures, and New Enterprise Associates

Series B (2019): $63M, investors not publicly disclosed

Key Investors in Imara

Bay City Capital

A venture capital firm founded in 1997 that specializes in life sciences, managing significant capital commitments to support companies achieving major therapeutic milestones.

Alexandria Venture Investments

The venture arm of a prominent real estate investment trust that provides critical infrastructure and capital to the life sciences, biotechnology, and pharmaceutical sectors.

Lundbeckfond Ventures

A commercial research foundation based in Denmark that maintains an international portfolio of venture capital and biotech companies, with a strong focus on biomedical research.

What's next for Imara?

With the recent influx of capital, Imara is well-positioned to accelerate its clinical development roadmap. The strategic focus remains on the successful execution of the ongoing Phase 2a trials for IMR-687, while simultaneously preparing for the regulatory and operational complexities of pediatric clinical trials. As the company matures, the emphasis will likely shift toward data readout milestones and potential commercialization strategies for its lead candidate. The firm's ability to maintain its momentum in the competitive biotech landscape will depend on its continued success in demonstrating the efficacy and safety of its PDE9 inhibitor platform across diverse patient demographics.

See full Imara company page

See More Financial Insights